Loading organizations...
Key people at Nelsen Biomedical.
Nelsen Biomedical operates as a life sciences strategy consulting firm, specializing in guiding organizations through complex market dynamics. The firm offers comprehensive services encompassing market opportunity definition, strategic plan development and execution, partnership facilitation, and value proposition positioning. Its approach leverages a deep understanding of the life sciences ecosystem to drive business growth and commercialization.
The company was founded by Barbara Nelsen, PhD, MBA, bringing over two decades of experience in research and development, business, and strategic development within the life science industry. Her extensive background includes roles as an investor, scientific investigator, and a leader in industry R&D and business development, such as with MGI Pharma. This multidisciplinary pedigree informed the establishment of a firm designed to bridge scientific innovation with robust business strategy.
Nelsen Biomedical serves a diverse client base, ranging from early-stage startups to established corporations, venture capital firms, research institutions, and government agencies. The firm’s overarching vision is to assist clients in mastering the business of science, enabling them to navigate the journey from scientific concept through to successful commercialization and sustainable growth.
Nelsen Biomedical is a life sciences strategy consulting firm specializing in defining market opportunities, developing, and implementing strategic plans for biotech and life sciences companies.[1][3] Founded by Barbara Nelsen, it helps build businesses in the industry by leveraging her 20+ years of experience in R&D, business, and strategic development, with offices in Minneapolis and Boston to connect Midwest clients to East Coast and Silicon Valley resources.[3][4][5] The firm generates around $14 million in revenue and operates in biotechnology and business services, focusing on high-impact areas like cell therapy and gene editing.[2][4]
Nelsen Biomedical was founded by Barbara Nelsen, a life sciences strategist with over two decades in R&D, business development, and strategy.[3][5] The idea emerged from Minnesota's nascent biotech scene, prompting expansion from a Minneapolis base to a Boston office in 2013 to bridge regional gaps and access major industry hubs.[4] Key pivotal moments include Nelsen's involvement in innovative projects, such as highlighting breakthroughs in CAR-T cell therapy (e.g., Novartis' Kymriah with 83% remission rates) and supporting Midwest firms like Wilson Wolf on cell therapy cost-of-goods-sold challenges.[4]
Nelsen Biomedical rides the wave of regenerative medicine and advanced biotech trends, such as CAR-T therapies achieving long-term cancer remissions (e.g., five-year cancer-free outcomes akin to the pacemaker's impact) and scalable gene editing.[4] Timing is ideal amid biotech's shift toward one-and-done treatments and cost reductions in cell therapy, fueled by market forces like FDA approvals and university spinouts (e.g., B-MoGen from University of Minnesota).[4][6] It influences the ecosystem by fostering Midwest growth, advising on immune programming at scale for infectious diseases, and building connections that accelerate regional innovation.[4][6]
Nelsen Biomedical is poised to expand its influence as biotech matures, particularly in cell/gene therapies and tools from firms like B-MoGen and Bio-Techne, amid rising demand for strategic guidance in a fragmented industry.[4] Trends like unprecedented immune programming and COGS breakthroughs in cell therapy will shape its trajectory, potentially amplifying its role in bridging heartland biotech to global hubs.[4][6] Its network-driven model positions it to drive more university-backed ventures, evolving from consultant to key ecosystem architect in life sciences' next phase of transformative solutions.
Key people at Nelsen Biomedical.
